内容摘要：Andreas Tompros tours Ridgecrest Avocados in Somis, Calif., on Thursday, May 15, 2025. (AP Photo/Damian Dovarganes)

Andreas Tompros tours Ridgecrest Avocados in Somis, Calif., on Thursday, May 15, 2025. (AP Photo/Damian Dovarganes)

Convincing soldiers to operate lawfully when they see their enemy using questionable practices is difficult, said Michael Schmitt, a distinguished professor of international law at the U.S. Military Academy at West Point. Israeli officials and other observers say Hamas uses civilians as shields as it embeds itself in communities, hiding fighters in hospitals and schools.“It’s really a heavy lift to look at your own soldiers and say you have to comply,” Schmitt said.

One soldier told the AP his unit tried to refuse to use human shields in mid-2024 but were told they had no choice, with a high-ranking officer saying they shouldn’t worry about international humanitarian law.The sergeant — speaking on condition of anonymity for fear of reprisal — said the troops used a 16-year-old and a 30-year-old for a few days.The boy shook constantly, he said, and both repeated “Rafah, Rafah” — Gaza’s southernmost city, where more than 1 million Palestinians had fled from fighting elsewhere at that point in the war.

It seemed they were begging to be freed, the sergeant said.Masoud Abu Saeed said he was used as a shield for two weeks in March 2024 in the southern city of Khan Younis.

“This is extremely dangerous,” he recounted telling a soldier. “I have children and want to reunite with them.”

The 36-year-old said he was forced into houses, buildings and a hospital to dig up suspected tunnels and clear areas. He said he wore a first-responder vest for easy identification, carrying a phone, hammer and chain cutters.GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They

and can produce side effects that include nausea and stomach pain.In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with

and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics.After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group.